SCHEMBL23218023

SCHEMBL23218023

CC(C)(CCCCC(C)(C)C(=O)OCCl)C(=O)OCCl

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.55
CYP4A11 Q02928 2/20 0.55
ACLY P53396 1/20 0.36
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35
ELANE P08246 2/20 0.33
THRB P10828 1/20 0.33
PKM P14618 1/20 0.33
HTT P42858 1/20 0.32
FFAR1 O14842 1/20 0.32
CPT2 P23786 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
PRKCA P17252 1/20 0.31
MEN1 O00255 1/20 0.30
MAPT P10636 1/20 0.30
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2219008 0.90 CYP4F2 (0.56) CYP4F2CYP4A11ELANEMEN1MAPT
SCHEMBL5799571 0.90 CYP4F2 (0.50) CYP4F2CYP4A11ELANETHRBPKM
SCHEMBL12819748 0.84 CYP4F2 (0.44) CYP4F2CYP4A11ELANETDP1MEN1
SCHEMBL26109757 0.82 CYP4F2 (0.40) CYP4F2CYP4A11
SCHEMBL16869114 0.81 CYP4F2 (0.39) CYP4F2CYP4A11PKMPRKCA
SCHEMBL300 0.80
SCHEMBL28404067 0.79 CYP4F2 (0.68) CYP4F2CYP4A11ACLYELANETHRB
SCHEMBL1996294 0.79 CYP4F2 (0.38) CYP4F2CYP4A11
SCHEMBL9483233 0.78 CYP4F2 (0.47) CYP4F2CYP4A11ACLYTDP1
SCHEMBL2993978 0.78 CYP4F2 (0.71) CYP4F2CYP4A11ACLYACACBACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067651-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS BIOHAVEN THERAPEUTICS LTD. 2024-02-29 US disclosed
US-20240067651-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS BIOHAVEN THERAPEUTICS LTD. 2024-02-29 US disclosed
US-20240067651-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS BIOHAVEN THERAPEUTICS LTD. 2024-02-29 US disclosed
CN-114945573-A Prodrugs of myeloperoxidase inhibitors 拜奥海芬治疗学有限公司 2022-08-26 CN disclosed
EP-4041735-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS Biohaven Therapeutics Ltd. (US) 2022-08-17 EP disclosed
WO-2021072140-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS BIOHAVEN THERAPEUTICS LTD. (US) 2021-04-15 WO disclosed
WO-2021072140-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS BIOHAVEN THERAPEUTICS LTD. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067651-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS MPO, CAT, SOD1 CYP4F2 2842/4885CYP4A11 3062/4885ACLY 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.